Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Frequently asked questions
What sector does STLN (STLN) operate in?
STLN belongs to the Other sector and operates in the Medical Care Facilities industry.
What is STLN (STLN) current stock price?
As of the latest data, STLN stock price is $6.29, with a previous close of $6.71. STLN lost -$0.42 in the last trading session, representing a -6.26% loss.
What is STLN (STLN) current market capitalization?
STLN market cap is approximately 641.05 million.
What is STLN (STLN) Earnings Per Share (EPS)?
The trailing EPS is -$0.29.
What is STLN (STLN) EBITDA?
STLN EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.09 million.
Does STLN (STLN) pay dividends?
No. STLN does not pay a dividend.
How did STLN (STLN) perform in its most recent earnings report?
In the last report (June 30, 2026), STLN posted an EPS surprise of -14.29% and a revenue surprise of 3.92%.
When is STLN (STLN) next earnings report?
STLN is expected to release its next earnings report on September 30, 2026.
What is STLN (STLN) beta (volatility) score?
STLN has a beta of 0.420, indicating lower volatility than the overall market.